Joint Formulary & PAD

Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Search

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Pain (Cannabis (medicinal) - Pain )

Records returned : 62 (on 29 May 2025 at 13:31:17). Return to search results for ' Pain '.

Show Icon and Status Keys

Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
1.
Drug:
Indication :
Status :
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
2.
Drug:
Indication :
Status :
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
3.
Drug:
Indication :
Status :
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
4.
Drug:
Indication :
Status :
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
5.
Drug:
Indication :
Status :
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
Guidelines SPC
CD
NFD1
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
Tablets can be dissolved in water (off-label)
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Oral solution
Restrictions / Comments:

Important
Codeine phosphate oral solution 25mg/5ml. Codeine linctus 15mg/5ml is ONLY licensed for cough.
 
Links :
Indication :
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

 
Links :
Indication :
Status :
Green
Formulations :
  • Oral solution
  • Tablets
Restrictions / Comments:

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Modified release tablets
Restrictions / Comments:

Important
Consider use if standard release tablets are not tolerated or compliance is an issue.
 
Links :
Indication :
Status :
Green
Formulations :
  • Oral suspension
  • Tablets
Restrictions / Comments:

 
Links :
Indication :
Status :
Red
Formulations :
  • Intravenous infusion
Restrictions / Comments:

Important
Restricted for patients where an oral NSAID is not suitable.
 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Preferred
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Effervescent tablets
  • Soluble tablets
  • Suppositories
Restrictions / Comments:

Important
Reserve for patients who cannot swallow solid dose forms. Soluble / effervescent preparations have a high sodium content and more expensive than ordinary tablets. Suppositories for use when oral route is not suitable
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Oral suspension
Restrictions / Comments:

Important
120mg/5ml and 250mg/5ml reserved for patients who cannot swallow solid dose forms or where sodium content of dispersible preparations is a problem. Non-formulary: Paracetamol oral suspension 500mg/5ml. Much more expensive. Use a soluble formulation.
 
Links :
Indication :
Status :
Red
Formulations :
  • Intravenous infusion
Restrictions / Comments:

Important
Prescribe in milligrams for doses <1g. Review infusion prescriptions after 48-72 hours. Note risk of overdose with IV paracetamol.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Patches
Restrictions / Comments:

Important
Prescribe by brand. Care: available as 3-day, 4-day and 7-day patches. Refer to Trust / Primary Care Pharmacy advice for locally preferred brands
 
Links :
Indication :
Status :
Blue
Formulations :
  • Sublingual tablets
Restrictions / Comments:

Important
Use in patients unable to tolerate oral medications or where morphine is contra-indicated. If this formulation is indicated, prescribing may be initiated and stabilised by a specialist service but has the potential to transfer to primary care WITHOUT a formal shared care agreement. In some circumstances a specialist may recommend that prescribing can be started in primary care
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
Fixed combinations are less preferable. Low dose (8/500 co-codamol) not recommended. Secondary Care - for A&E / discharge only.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Capsules
Restrictions / Comments:

Important
Capsules are more costly than tablets in primary care. Fixed combinations are less preferable. Low dose (8/500 co-codamol) not recommended.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Effervescent tablets
Restrictions / Comments:

Important
Fixed combinations are less preferable. Low dose (8/500 co-codamol) not recommended. Avoid effervescent formulations (high sodium content and more costly). Reserve for swallowing difficulties or patients with feeding tubes. Secondary Care - for A&E / discharge only.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
Fixed combinations are less preferred. RSCH - prescribe as separate components - combination is non-formulary at RSCH. The MHRA advises when prescribing dihydrocodeine with paracetamol, the tablet strength and dose must be clearly indicated
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Immediate release tablets
  • Oral solution
  • Oro-dispersible
Restrictions / Comments:

Important
Orodispersible tablets are a cost-effective alternative to oral solution. Reserve oral solution and orodispersible tablets for patients in whom a solid dose form is not suitable.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Capsules (slow release)
  • Granules (slow release)
  • Tablets (slow release)
Restrictions / Comments:

Important
Prescribe modified-release preparations by brand - refer to local guidelines for preferred brands. Zomorph capsules (12-hourly) can be opened for administration in patients unable to swallow the capsules.
 
Links :
Indication :
Status :
Red
Formulations :
  • Injection
  • Solution for infusion
Restrictions / Comments:

Important
See separate listing for palliative care
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Suppositories
Restrictions / Comments:

 
Links :
Guidelines SPC
CD
NFD1
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
Reserve for when alternatives are contraindicated or ineffective. At RSFT - initiation by pain team only.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Capsules
  • Oral solution
Restrictions / Comments:

Important
For patients unable to tolerate / poor response to morphine. Modified-release preparations to be prescribed by brand
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Modified release tablets
Restrictions / Comments:

Important
For use in patients where morphine sulfate is not suitable / not tolerated. Modified-release preparations to be prescribed by brand
 
Links :
Indication :
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

Important
Alternative for patients unable to tolerate / poor response to morphine. Care with dose conversion.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Capsules
Restrictions / Comments:

Important
Consider use where maximum tolerated doses of codeine / dihydrocodeine are ineffective.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Modified release capsules
  • Modified release tablets
Restrictions / Comments:

Important
Branded prescribing is recommended for modified release tramadol. Do not confuse 12 hourly and 24 hourly preparations. Consider tramadol where maximum tolerated doses of codeine / dihydrocodeine are ineffective.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Soluble tablets
Restrictions / Comments:

Important
Reserved for patients unable to swallow solid dose forms or for administration via an enteral tube. Consider use where maximum tolerated doses of codeine / dihydrocodeine are ineffective.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Oro-dispersible
Restrictions / Comments:

Important
Reserved for patients unable to swallow solid dose forms or for administration via an enteral tube. Consider use where maximum tolerated doses of codeine / dihydrocodeine are ineffective.
 
Links :
Indication :
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Oral solution
Restrictions / Comments:

 
Links :
Guidelines SPC
CD
NFD1
Indication :
Status :
Non Formulary
Formulations :
  • Oral drops
Restrictions / Comments:

 
Links :
Guidelines SPC
CD
NFD1
Indication :
Status :
Blue
Formulations :
  • Patches
Restrictions / Comments:

Important

Prescribe by brand in Primary Care. Not for use in opioid naïve patients. Limited place in therapy - on specialist advice only

 
Links :
Indication :
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

Important
See separate listing for use in assisted ventilation and anaesthesia
 
Links :
Indication :
Status :
Red
Formulations :
  • Injection
  • Nasal spray
Restrictions / Comments:

Important
100mcg in 2ml injection used intranasally in paediatrics for painful procedures.
 
Links :
Guidelines SPC
CD
Un
Indication :
Status :
Non Formulary
Formulations :
  • Buccal tablets
  • Buccal/sublingual
  • Lozenges
  • Nasal spray
  • Sublingual tablets
Restrictions / Comments:

Important
Immediate release fentanyl preparations are non-formulary for all pain indications EXCEPT for breakthrough pain in patients receiving opioid therapy for cancer pain.
 
Links :
Guidelines SPC
CD
NFD1
Indication :
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

Important
See separate listings for palliative care and use in anaesthesia.
 
Links :
Indication :
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

Important
Limited stock - restrictions apply. Contact Pharmacy. Safety alert for High Dose
 
Links :
Indication :
Status :
Red
Formulations :
  • Oral solution
Restrictions / Comments:

Important

On advice of Pain Team, Consultant Anaesthetist, Intensivist only.

 
Links :
Indication :
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

Important

On advice of Pain Team, Consultant Anaesthetist, Intensivist only.

Note - injection may be used sublingually or by buccal route (off-label use)

 
Links :
Indication :
Status :
Red
Formulations :
  • Intramuscular injection (IM)
Restrictions / Comments:

Important
Obstetric analgesia
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important
Tablets - Not for chronic or acute, non-malignant pain. Intramuscular injection used in obstetric pain.
 
Links :
Indication :
Status :
Red
Formulations :
  • Inhalation
Restrictions / Comments:

Important

Acute, trauma pain.

RSFT - for

  • use during removal of brachytherapy
  • transperineal prostate biopsies
  • pain management during diagnostic / therapeutic procedures
  • pain management by the acute pain team for adult non-obstetric patients
 
Links :
Indication :
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

Important
Acute pain, including obstetric analgesia
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

 
Links :
Guidelines SPC
CD
NFD2
Indication :
Status :
Red
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
Indication :
Status :
Non Formulary
Restrictions / Comments:

Important
This status applies to the use of aspirin for pain. Refer to separate formulary entries for caridology indications.
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important
Fixed combinations are less preferred. The MHRA advises when prescribing dihydrocodeine with paracetamol, the tablet strength and dose must be clearly indicated
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important
Fixed combinations are less preferred. The MHRA advises when prescribing dihydrocodeine with paracetamol, the tablet strength and dose must be clearly indicated
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

Important
No longer licensed because of safety concerns, particularly toxicity in overdose.
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

Important
Not for chronic or acute, non-malignant pain. See separate formulary entry for use in neuropathic pain.
 
Links :
Guidelines SPC
CD
NFD1
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
Guidelines SPC
CD
NFD2
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

Important
Not for chronic or acute, non-malignant pain. See separate formulary entry for use in neuropathic pain
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Sublingual tablets
Restrictions / Comments:

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
Guidelines SPC
CD
NFD1